Actuate Therapeutics Signs $100M Sales Agreement
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Actuate Therapeutics, Inc. ( (ACTU) ) is now available.
On November 28, 2025, Actuate Therapeutics, Inc. entered into an At the Market Issuance Sales Agreement with B. Riley Securities, Inc. and Craig-Hallum Capital Group LLC to offer and sell shares of its common stock, with an aggregate offering price of up to $100 million. This agreement allows the company to sell shares through the Sales Agents, who will receive a commission of up to 3% of the gross sales proceeds, potentially impacting the company’s capital-raising efforts and market presence.
The most recent analyst rating on (ACTU) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Actuate Therapeutics, Inc. stock, see the ACTU Stock Forecast page.
More about Actuate Therapeutics, Inc.
Average Trading Volume: 70,463
Technical Sentiment Signal: Sell
Current Market Cap: $160.4M
For an in-depth examination of ACTU stock, go to TipRanks’ Overview page.
